Home»Exposition»Frontier Pharma: First-in-Class Innovation in Hematological Cancers – With Over 1,450 Programs in Active Development – Research and Markets

Frontier Pharma: First-in-Class Innovation in Hematological Cancers – With Over 1,450 Programs in Active Development – Research and Markets

0
Shares
Pinterest Google+

DUBLIN, June 19, 2017 /PRNewswire/ —
Research and Markets has announced the addition of the “Frontier Pharma: First-in-Class Innovation in Hematological Cancers – Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline” drug pipelines to…

Previous post

Global Contact Center Workforce Optimization Market Share Report 2017 - Research and Markets

Next post

Philippines Mattress Market Outlook to 2021 - Transformation of Rural to Urban Augmenting Market Growth - Research and Markets